DeepMed Research

BAXTER HEALTHCARE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers

Not Applicable

Withdrawn

Conditions: Venous Leg Ulcers

Interventions: Device: Unite Biomatrix

First Posted Date: 2009-08-06

Last Posted Date: 2017-04-05

Lead Sponsor: Baxter Healthcare Corporation

Registration Number: NCT00953563

Locations: 🇺🇸
University of Miami, Miller School of Medicine, Miami, Florida, United States
🇺🇸
UCSD Medical Center, San Diego, California, United States
🇺🇸
Newbridge Medical Research Corp., Warren General Hosp., Warren, Pennsylvania, United States

Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock

Not Applicable

Completed

Conditions: Sepsis

Interventions: Other: Standard treatment
Device: Cascade

First Posted Date: 2009-06-17

Last Posted Date: 2025-03-13

Lead Sponsor: Vantive Health LLC

Target Recruit Count: 60

Registration Number: NCT00922870

Locations: 🇫🇷
Hopital Le Bocage, Dijon, France
🇫🇷
CHU hospital, Clermont-Ferrand, France
🇫🇷
Centre Hospitalier Marc JACQUET, Melun, France

and more 2 locations

FS VH S/D 500 S-apr in Vascular Surgery

Phase 3

Completed

Conditions: Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses

Interventions: Biological: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Other: Surgical gauze pads

First Posted Date: 2009-05-05

Last Posted Date: 2012-11-27

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 176

Registration Number: NCT00892957

High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock

Not Applicable

Terminated

Conditions: Kidney Failure, Acute
Systemic Inflammatory Response Syndrome

Interventions: Device: continuous venovenous hemodialysis

First Posted Date: 2009-04-06

Last Posted Date: 2025-03-13

Lead Sponsor: Vantive Health LLC

Target Recruit Count: 80

Registration Number: NCT00875888

Locations: 🇩🇪
Medizinische Klinik mit Schwerpunkt Nephrologie Charite, Campus Mitte, Berlin, Germany
🇩🇪
Charité-Virchow Klinik, Berlin, Germany
🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany

and more 1 locations

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

Phase 4

Completed

Conditions: Dehydration

Interventions: Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

First Posted Date: 2008-12-12

Last Posted Date: 2011-10-26

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 100

Registration Number: NCT00807885

Locations: 🇺🇸
MDS Pharma Services, Neptune, New Jersey, United States

Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line

Not Applicable

Completed

Conditions: Chronic Kidney Failure

Interventions: Device: Standard blood line
Device: Cartridge blood set

First Posted Date: 2008-12-08

Last Posted Date: 2025-03-13

Lead Sponsor: Vantive Health LLC

Target Recruit Count: 16

Registration Number: NCT00804453

Locations: 🇫🇷
AURAL, Bourgoin Jallieu, France

Reduction of Heparin Dose in Dialysis With Evodial System

Not Applicable

Completed

Conditions: Chronic Kidney Failure

Interventions: Device: Evodial hemodialysers and Evodia blood lines

First Posted Date: 2008-10-29

Last Posted Date: 2025-03-13

Lead Sponsor: Vantive Health LLC

Target Recruit Count: 53

Registration Number: NCT00781690

Locations: 🇸🇪
Karolinska Hospital, Stockholm, Sweden
🇫🇷
Hopital Brabois, Vandoeuvre les Nancy, France
🇫🇷
Clinique St Exupéry, Toulouse, France

and more 4 locations

Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)

Phase 2

Completed

Conditions: Anesthesia

Interventions: Drug: sevoflurane/nitrous oxide
Drug: desflurane
Drug: desflurane/nitrous oxide

First Posted Date: 2008-09-30

Last Posted Date: 2019-03-08

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 216

Registration Number: NCT00762372

Locations: 🇯🇵
Tokyo University, Tokyo, Japan
🇯🇵
Keio University, Tokyo, Japan
🇯🇵
Okayama University, Okayama, Japan

and more 12 locations

Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures

Phase 2

Completed

Conditions: Facial Rhytidectomy (Face-lift)

Interventions: Biological: Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)

First Posted Date: 2008-07-02

Last Posted Date: 2012-10-23

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 45

Registration Number: NCT00708071

Fibrin Sealant for the Sealing of Dura Sutures

Phase 2

Completed

Conditions: Pathological Processes in the Posterior Fossa
Dura Defects

Interventions: Biological: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Procedure: Standard of care

First Posted Date: 2008-05-21

Last Posted Date: 2013-06-27

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 95

Registration Number: NCT00681824

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy